Subscribe to RSS
Download PDF
DOI: 10.5999/aps.2017.44.5.378
Effects of Topical Tamoxifen on Wound Healing of Burned Skin in Rats
Authors
We thank Dr. Ali Zamani, the Quality Assurance Manager of the Pars Darou Pharmaceutical Company for preparing the drug, and Dr. Mohammad Hosien Kalantar Motamedi for his kind assistance in editing this paper.
Background This study aimed to assess the effects of the topical application of tamoxifen on wound healing of burned skin in Wistar rats by evaluating 3 healing characteristics: fibrotic tissue thickness (FTT), scar surface area (SSA), and angiogenesis in the healed scar tissue.
Methods Eighteen male Wistar rats were used in this study. A third-degree burn wound was made on the shaved animals’ back, measuring 2×2×2 cm. In the first group, a 2% tamoxifen ointment was applied to the wound twice daily for 8 weeks. The second group received a placebo ointment during the same period. The third group did not receive any treatment and served as the control group.
Results The median (interquartile range=[Q1, Q3]) FTT was 1.35 (1.15, 1.62) mm, 1.00 (0.95, 1.02) mm, and 1.25 (0.8, 1.5) mm in the control, tamoxifen, and placebo groups, respectively (P=0.069). However, the FTT in the tamoxifen group was less than in the placebo and control groups. The median angiogenesis was 3.5 (3.00, 6.25), 8.00 (6.75, 9.25), and 7.00 (5.50, 8.25) vessels per high-power field for the control, tamoxifen, and placebo groups, respectively (P=0.067). However, the median angiogenesis was higher in the tamoxifen group than in the control group. No significant difference was observed in the mean SSA between the tamoxifen group and the control group (P=0.990).
Conclusions Local application of tamoxifen increased angiogenesis and decreased the FTT, with no change in the SSA in burned skin areas. These effects are expected to expedite the wound healing process, reducing contracture and preventing hypertrophic scar and keloid formation.
Publication History
Received: 13 November 2016
Accepted: 29 August 2017
Article published online:
20 April 2022
© 2017. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonCommercial License, permitting unrestricted noncommercial use, distribution, and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes. (https://creativecommons.org/licenses/by-nc/4.0/)
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
REFERENCES
- 1 Mustoe TA, Cooter RD, Gold MH. et al. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110: 560-71
- 2 Kuhn MA, Wang X, Payne WG. et al. Tamoxifen decreases fibroblast function and downregulates TGF (beta2) in dupuytren’s affected palmar fascia. J Surg Res 2002; 103: 146-52
- 3 Zhao JY, Chai JK, Song HF. et al. Effect of different concentration of tamoxifen ointment on the expression of TGF-beta2 of hypertrophic scar at rabbit ears. Zhonghua Zheng Xing Wai Ke Za Zhi 2011; 27: 213-7
- 4 Owens LV, Cance WG, Huth JF. Retroperitoneal fibrosis treated with tamoxifen. Am Surg 1995; 61: 842-4
- 5 Ruffy MB, Kunnavatana SS, Koch RJ. Effects of tamoxifen on normal human dermal fibroblasts. Arch Facial Plast Surg 2006; 8: 329-32
- 6 Mousavi SR, Raaiszadeh M, Aminseresht M. et al. Evaluating tamoxifen effect in the prevention of hypertrophic scars following surgical incisions. Dermatol Surg 2010; 36: 665-9
- 7 Carthy JM, Sundqvist A, Heldin A. et al. Tamoxifen inhibits TGF-β-mediated activation of myofibroblasts by blocking non-smad signaling through ERK1/2. J Cell Physio 2015; 230: 3084-92
- 8 Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg 2017; 43 Suppl 1: S3-18
- 9 Schouten HJ, Nieuwenhuis MK, van Zuijlen PP. A review on static splinting therapy to prevent burn scar contracture: do clinical and experimental data warrant its clinical application?. Burns 2012; 38: 19-25
- 10 Hu D, Hughes MA, Cherry GW. Topical tamoxifen: a potential therapeutic regime in treating excessive dermal scarring?. Br J Plast Surg 1998; 51: 462-9
- 11 Hu D, Zhu X, Xu M. et al. The inhibitory effect of tamoxifen on human dermal fibroblast-populated collagen lattices. Zhonghua Zheng Xing Wai Ke Za Zhi 2002; 18: 160-2
- 12 Pemmaraju N, Munsell MF, Hortobagyi GN. et al. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol 2012; 23: 1471-4
- 13 Sporn MB, Lippman SM. Agents for chemoprevention and their mechanism of action. In: Kufe DW, Pollock RE, Weichselbaum RR. et al. Holland-Frei cancer medicine. 6th ed. Hamilton: BC Decker; 2003
- 14 Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg 2006; 8: 362-8
- 15 Zurada JM, Kriegel D, Davis IC. Topical treatments for hypertrophic scars. J Am Acad Dermatol 2006; 55: 1024-31
- 16 Mikulec AA, Hanasono MM, Lum J. et al. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg 2001; 3: 111-4
- 17 Foo CW, Tristani-Firouzi P. Topical modalities for treatment and prevention of postsurgical hypertrophic scars. Facial Plast Surg Clin North Am 2011; 19: 551-7